Oral semaglutide was superior to placebo in reducing the risk of major adverse cardiovascular events, researchers reported in the SOUL trial involving over 9,600 adults with high-risk type 2 diabetes.
In WHI trial, hormone therapy reduced LDL and insulin resistance but raised triglycerides, with strongest lipoprotein(a) reductions seen in Native and Asian women.